Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HTX-011 for postoperative pain after unilateral open inguinal herniorrhaphy
2017-001636-19Phase 3Completed
- Sponsor
- Heron Therapeutics, Inc.
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine + meloxicam in postoperative pain (3 arms), sponsored by Heron Therapeutics, Inc. Primary endpoint: Mean area under the curve of Numeric Rating Scale pain intensity with activity through 72 hours. Started Aug 2017; status: completed.
02
Drugs
bupivacaine + meloxicam
03
Conditions
postoperative pain
Beyond the preview
Go deeper on 2017-001636-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001636-19.